Divis Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Divis Laboratories Ltd reported a 13.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.0%.
• Its expenses for the quarter were up by 8.5% QoQ and 13.1% YoY.
• The net profit increased 26.4% QoQ and increased 35.1% YoY.
• The earnings per share (EPS) of Divis Laboratories Ltd stood at 25.97 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Divis Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its robust R&D capabilities and manufacturing excellence. Recently, Divis Laboratories has been focusing on expanding its production capacity and enhancing its product portfolio to meet the growing demand in the global pharmaceutical market. While specific recent developments are not available, the company continues to maintain a strong presence in the industry, driven by its focus on quality and innovation.

Revenue

For the quarter ending Q2FY26, Divis Laboratories Ltd reported a total income of ₹2,860 crores. This represents a quarter-over-quarter (QoQ) increase of 13.1% from ₹2,529 crores in Q1FY26 and a year-over-year (YoY) rise of 17.0% from ₹2,444 crores in Q2FY25. The upward trend in revenue is indicative of the company's strong market position and ability to capture growth opportunities. The increase in total income over the quarters and years reflects the company's operational efficiency and market demand for its products.

Profitability

In terms of profitability, Divis Laboratories reported a profit before tax of ₹912 crores in Q2FY26, marking a 24.4% increase QoQ from ₹733 crores in Q1FY26, and a 26.3% rise YoY from ₹722 crores in Q2FY25. The company's profit after tax for the quarter stood at ₹689 crores, up by 26.4% QoQ from ₹545 crores in the previous quarter, and a 35.1% increase YoY from ₹510 crores. The tax expenses for the quarter were ₹223 crores, an 18.6% increase from the previous quarter and a 5.2% increase from the same quarter last year. The earnings per share (EPS) for Q2FY26 was ₹25.97, showing a 26.7% increase QoQ and a 35.3% increase YoY, underscoring the company's profitability growth over the periods analyzed.

Operating Metrics

The total expenses for Divis Laboratories in Q2FY26 were reported at ₹1,948 crores, which is an 8.5% increase QoQ from ₹1,796 crores in Q1FY26 and a 13.1% increase YoY from ₹1,722 crores in Q2FY25. The rise in expenses is consistent with the overall increase in revenue, suggesting effective cost management in the context of growing business operations. The company's ability to maintain a significant increase in profit before and after tax, despite rising expenses, highlights its operational efficiency. The financial data presented does not provide information on additional financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio, which would require further details beyond the data provided.